Davood KHoda Amorzideh on VTE and Bleeding in Cancer
Davood KHoda Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared on LinkedIn:
”In the AVERT post-hoc analysis, cancer patients at intermediate-high VTE risk (Khorana_score ≥2) with elevated baseline GDF_15 had increased VTE risk, while elevated NT proBNP and CRP levels predicted bleeding.
Increasing hs-TnT levels from baseline to 1 month was associated with increased VTE risk.
Steven Hawken, Marc Carrier, Philip Wells, Dylan Burger, Tzu-Fei Wang’‘
Read the full article here.
Article: Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers Open Access
Authors: Danielle Carole Roy , Tzu-Fei Wang , Ranjeeta Mallick , Dylan Burger , Marc Carrier , Philip Wells , Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers
-
May 12, 2026, 15:21Joseph Mmwa: Blood Donation Debate Sparks Concern Across Kenya
-
May 12, 2026, 15:20Wolfgang Miesbach: Roctavian Experience in Modern Hemophilia Gene Therapy
-
May 12, 2026, 15:16Abdul Mannan: Acquired Haemophilia A after Tozinameran
-
May 12, 2026, 15:14Jim Hoffman: Persistent EBV Infection and the Promise of NET-Targeted Treatment